Cellectar Biosciences, Inc. (CLRB)
NASDAQ: CLRB · Real-Time Price · USD
1.180
-0.210 (-15.11%)
At close: Oct 14, 2026, 4:00 PM EDT
1.220
+0.040 (3.39%)
Pre-market: Oct 15, 2026, 9:09 AM EDT
Cellectar Biosciences Employees
Cellectar Biosciences had 11 employees as of December 31, 2025. The number of employees did not change compared to the previous year. That makes Cellectar Biosciences the 39,893rd largest employer in the world and 5,987th in the United States.
Employees
11
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,029,427
Market Cap
11.15M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 11 | 0 | - |
| Dec 31, 2024 | 11 | -9 | -45.00% |
| Dec 31, 2023 | 20 | 5 | 33.33% |
| Dec 31, 2022 | 15 | 3 | 25.00% |
| Dec 31, 2021 | 12 | 1 | 9.09% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cerenome | 28 |
| Daré Bioscience | 24 |
| Citius Pharmaceuticals | 23 |
| IN8bio | 18 |
| Lipocine | 14 |
| Tvardi Therapeutics | 12 |
| Allarity Therapeutics | 8 |
| AEON Biopharma | 8 |
CLRB News
- 1 hour ago - Cellectar Biosciences presents efficacy data from CLOVER WaM trial - TheFly
- 2 hours ago - Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia - GlobeNewsWire
- 13 days ago - Cellectar Biosciences Slides: Corporate presentation - Filings
- 16 days ago - Cellectar Biosciences to present data from Phase 2 CLOVER WaM trial - TheFly
- 16 days ago - Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia - GlobeNewsWire
- 1 month ago - Cellectar Biosciences Transcript: Study update - Transcripts
- 1 month ago - Cellectar Biosciences Slides: Study update - Filings
- 1 month ago - Cellectar Biosciences Slides: Corporate presentation - Filings